| PlayDecide

HWSA Summer Camp

Policy
1	Since resources are limited, there should be a limit and only cost effective drugs that benefit the greater number of patients should be reimbursed. If a drug purchaser has to choose between treating 10 patients with drug A or 1 with drug B for a rare disease, then the choice should always be to treat 10 with drug A.
2	Only cost effective drugs should be reimbursed, but the approach for orphan drugs should be different than for common diseases. If there is any doubt about the cost effectiveness of an orphan drug, it should be exceptionally reimbursed in certain cases.
3	Like position 2, but if there is any doubt about the cost effectiveness of an orphan drug, the benefit of doubt should be given to the patient and the drug should be reimbursed systematically.
4	Health is a priority for European citizens. Just as efforts to rescue people after an accident are not restricted, efforts to rescue a patient with a rare disease should not be limited. Cost effectiveness should not be the parameter on which to base reimbursement decisions.

Overview of the new policies developed by players in this event.



European regulation defines what kind of tests may be performed and for which diagnosis. Patients should receive the results of the tests from a skilled health care professional.
European regulation defines what kind of tests may be performed and for which diagnosis. Patients should receive the results of the tests from a skilled health care professional.
National health care systems can decide on providing national neonatal screening for diseases that are treatable. An independent European body will coordinate and advise on what national neonatal screening should be in place and according to which code of practice. European legislation is needed to ensure and control the harmonization of the neonatal screening.


Cross border health-care is possible for patients only if treatment is not available in their country of residence. No prior authorization is needed. The state invests some in e-Health initiatives. If the patient is child or unable for independent living one carer costs must be reimbursed also, not only the expenses of the direct treatments.